Zobrazeno 1 - 10
of 91
pro vyhledávání: '"Kenneth A Kern"'
Autor:
Tian Zhang, Nicholas J Vogelzang, Daniel P Petrylak, Ravi A Madan, Karen A Autio, Ray Li, Helen Cho, Szu-Yu Tang, Celestia S Higano, Luke Nordquist, Leonard J Appleman, Xin-Hua Zhu, Hani Babiker, Sandip M Prasad, Michael T Schweizer, Stephane Billotte, Nora Cavazos, Orlaith Bogg, Kam Chan, Megan Kaneda, I-Ming Wang, Jenny Zheng, Robert Hollingsworth, Kenneth A Kern
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Background This phase 1 study evaluated PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in two clinical states of prostate cancer (PC), metastatic castration-resistant PC (mCRPC) and biochemical recurrence (BCR).Methods For dose escal
Externí odkaz:
https://doaj.org/article/a4a8a3a078ab4567a1641ae4c2b5d1db
Autor:
Patricia M. LoRusso, Kenneth A. Kern, Karen R. McLachlan, Patricia A. English, Jennifer M. Reynolds, Xianxian Zheng, Rossano Cesari, M. Naveed Shaik, Bo Huang, Arvind Dasari, Antonio Jimeno, James M. Cleary, Geoffrey I. Shapiro, Wells A. Messersmith
Purpose: To estimate the maximum tolerated dose (MTD) for continuous oral administration of the γ-secretase inhibitor PF-03084014, determine the recommended phase II dose (RP2D), and evaluate safety and preliminary activity in patients with advanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15bd94532ba2fa13f8f6f263e26aff1b
https://doi.org/10.1158/1078-0432.c.6523016.v1
https://doi.org/10.1158/1078-0432.c.6523016.v1
Autor:
Patricia M. LoRusso, Kenneth A. Kern, Karen R. McLachlan, Patricia A. English, Jennifer M. Reynolds, Xianxian Zheng, Rossano Cesari, M. Naveed Shaik, Bo Huang, Arvind Dasari, Antonio Jimeno, James M. Cleary, Geoffrey I. Shapiro, Wells A. Messersmith
Supplemental Table S1. Tumor responses to single-agent treatment with PF-03084014 in patients with advanced solid malignancies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ee99a04b949092c73b488cf2938c43c
https://doi.org/10.1158/1078-0432.22455392.v1
https://doi.org/10.1158/1078-0432.22455392.v1
Autor:
Patricia M. LoRusso, Kenneth A. Kern, Karen R. McLachlan, Patricia A. English, Jennifer M. Reynolds, Xianxian Zheng, Rossano Cesari, M. Naveed Shaik, Bo Huang, Arvind Dasari, Antonio Jimeno, James M. Cleary, Geoffrey I. Shapiro, Wells A. Messersmith
Supplemental Figure S1 and Figure S2. Figure S1: Pharmacokinetic profiles of PF-03084014 following administration to patients with solid malignancies. Figure S2. Downregulation of Hes4 gene expression following treatment with PF-03084014 in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10eaa9a92aa1220bf80019b2b7576449
https://doi.org/10.1158/1078-0432.22455395.v1
https://doi.org/10.1158/1078-0432.22455395.v1
Autor:
Giuseppe Curigliano, Geoffrey I. Shapiro, Rebecca S. Kristeleit, Albiruni R. Abdul Razak, Stephen Leong, Maria Alsina, Antonio Giordano, Karen A. Gelmon, Erica Stringer-Reasor, Ulka N. Vaishampayan, Mark Middleton, Anthony J. Olszanski, Hope S. Rugo, Kenneth A. Kern, Nuzhat Pathan, Rachelle Perea, Kristen J. Pierce, Sarah C. Mutka, Zev A. Wainberg
Publikováno v:
British journal of cancer. 128(1)
This Phase 1b study (B2151002) evaluated the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with other anti-tumour agents in advanced solid tumours.Patients with various malignancies were administered gedatolisib (90‒310 mg intravenou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e1818b1cd7a3a5f0aea8ef2fee63c16
https://pubmed.ncbi.nlm.nih.gov/36335217
https://pubmed.ncbi.nlm.nih.gov/36335217
Autor:
Karen A Autio, Celestia S Higano, Luke Nordquist, Leonard J Appleman, Tian Zhang, Xin-Hua Zhu, Hani Babiker, Nicholas J Vogelzang, Sandip M Prasad, Michael T Schweizer, Ravi A Madan, Stephane Billotte, Nora Cavazos, Orlaith Bogg, Ray Li, Kam Chan, Helen Cho, Megan Kaneda, I-Ming Wang, Jenny Zheng, Szu-Yu Tang, Robert Hollingsworth, Kenneth A Kern, Daniel P Petrylak
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e005702
BackgroundThis phase 1 study evaluated PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in two clinical states of prostate cancer (PC), metastatic castration-resistant PC (mCRPC) and biochemical recurrence (BCR).MethodsFor dose escalat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ec4892a94d6256bc2746b04b68ab404
https://doi.org/10.1136/jitc-2022-005702
https://doi.org/10.1136/jitc-2022-005702
Autor:
Giuseppe Curigliano, Geoffrey I. Shapiro, Rebecca S. Kristeleit, Albiruni R. Abdul Razak, Stephen Leong, Maria Alsina, Antonio Giordano, Karen A. Gelmon, Erica Stringer-Reasor, Ulka N. Vaishampayan, Mark Middleton, Anthony J. Olszanski, Hope S. Rugo, Kenneth A. Kern, Nuzhat Pathan, Rachelle Perea, Kristen J. Pierce, Sarah C. Mutka, Zev A. Wainberg
Publikováno v:
Br J Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb0c5887cbae60c074f6fb77bd92e82c
https://doi.org/10.1038/s41416-023-02161-w
https://doi.org/10.1038/s41416-023-02161-w
Autor:
Brett E. Houk, HS Han, Elizabeth Claire Dees, Aditya Bardia, Robert Wesolowski, Kristen J. Pierce, R Perea, HS Rugo, Peter Kabos, Kenneth A. Kern, Andres Forero
Publikováno v:
Cancer Research. 78:OT2-07
Background:Hormone receptor positive (HR+) disease is the most common subset of advanced breast cancer (BC). The majority of women with HR+ metastatic BC (MBC) develop resistance to endocrine therapy (ET), with a median survival of 2-3 years. A new s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff208be67733f0287e63249eb80ddb35
https://doi.org/10.1158/1538-7445.sabcs17-ot2-07-06
https://doi.org/10.1158/1538-7445.sabcs17-ot2-07-06
Autor:
Stephane Billotte, Sandip M. Prasad, Michael T. Schweizer, Helen Kim Cho, Nora Cavazos, Tian Zhang, Michael R. Dermyer, Karen A. Autio, Daniel P. Petrylak, Kam Chan, Leonard Joseph Appleman, Nicholas J. Vogelzang, Robert Hollingsworth, Xinhua Zhu, Ruifeng Li, Kenneth A. Kern, Hani M. Babiker, Celestia S. Higano, Joseph John Binder, Luke T. Nordquist
Publikováno v:
Journal of Clinical Oncology. 39:2612-2612
2612 Background: Therapeutic vaccines targeting PC-associated antigens represent attractive approaches in combination with immune checkpoint inhibitors (ICI). Safety/antitumor activity of PF-06753512 (PrCa VBIR) was evaluated in a phase I, dose-escal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04189acbd832508439236da08da02c98
https://doi.org/10.1200/jco.2021.39.15_suppl.2612
https://doi.org/10.1200/jco.2021.39.15_suppl.2612
Autor:
Kenneth A. Kern
Publikováno v:
Journal of Oncology Practice. 12:e810-e817
Breakthrough therapy designation (BTD) is a new approach created by the US Congress and the US Food and Drug Administration (FDA) as part of the FDA Innovation and Safety Act of 2012 to expedite the drug development process for serious illness, inclu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61731109c103f42a07f67cbcbe63c696
https://doi.org/10.1200/jop.2016.012161
https://doi.org/10.1200/jop.2016.012161